May 28 (Reuters) - (This May 28 story has been corrected to say 'eye drop,' not 'liquid medication,' in paragraph 3 and to remove the picture) Eye-care drugmaker Alcon (ALCC.S), opens new tab said ...

Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease By Kevin Dunleavy May 29, 2025 10:20am Alcon Novartis FDA approval dry eye disease ...

Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.

GENEVA, May 28, 2025--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease ...

Alcon Announces FDA Approval of ... one drop per eye, two times a day. 3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other ...

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye ...

TRYPTYR will be available in single-dose vials, administered as one drop per eye twice daily. Alcon plans to launch the product in the U.S. in the third quarter of 2025 and aims to introduce it to ...

TRYPTYR is available in easy-to-use, single dose vials: one drop per eye, two times a day. 3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing ...

DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.5-7 Many commonly used DED treatment ...